Lördag 21 December | 18:12:49 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-12 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-15 07:00 Kvartalsrapport 2025-Q1
2025-02-20 08:00 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-10-02 07:00:00

Bergen, Norway, 2 October 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce that we have completed a successful production based on automated processes of our glucose sensor, Sencell.

Reference is made to the Q2 report when the company described the necessary steps of preparations towards automated production. Lifecare’ manufacturing department has successfully executed production of Sencell sensors at our laboratory in Reutlingen, based on automated processes. These processes will now be repeated at our production facilities in Mainz.

- At the end of the 1st quarter, we reached our goal of successful pilot production of Sencell. We have now automated the most critical steps in the production process, transitioning from partially hand-made sensors towards automated production. The achievement demonstrates our ability to conduct automated production of glucose monitoring sensors for both humans and pets, says CEO Joacim Holter.

The sensors that have been produced are now subject to internal in vitro sensor quality control and bacteriological testing. Subject to quality approval, the newly manufactured sensors will be used in the second phase of the longevity study organized by Lifecare Veterinary, starting in the next few weeks.

The automated production process involves two key steps. The first step is a sophisticated deposition process conducted within a Scanning Electron Microscope (SEM), using customized software to produce the Sencell sensor. The second step involves an automated process for filling Lifecare’s proprietary and patented glucose-reactive chemical solution into the nanosized chambers of the sensors. This step also includes applying nano-porous membranes to seal the chambers after filling. To accomplish this, Lifecare’s production team utilizes advanced and customized equipment for automated production processes.

- We are very pleased that our innovative glucose sensor, which has a complex structure, can also be produced based on the automatically processes with the equipment that we have invested in and spent time adapting to our production purpose. While the current automated production is not at a volume scale, it significantly enhances the efficiency of the process and increases sensor output. We will now repeat the production based on automated processes at our pilot manufacturing unit in Mainz and continue the process improvements towards scalable production, says Holter.